drugset / Trial / NCT01993160

18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer

NCT01993160

NaSingle-groupOpen-labelDiagnostic

Summary

This is a single centre, single arm feasibility study of 18FCH PET-MR imaging for staging patients with high risk prostate cancer. Study Hypothesis: FCH-PET/MR will enable more accurate staging of patients with high risk prostate cancer as compared to conventional imaging.

Timeline

Start
2013-12
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject fluorocholine Diagnostic / imaging agent Intravenous

Indications